441 related articles for article (PubMed ID: 30499732)
41. Long-acting reversible contraception immediately after medical abortion: systematic review with meta-analyses.
Schmidt-Hansen M; Hawkins JE; Lord J; Williams K; Lohr PA; Hasler E; Cameron S
Hum Reprod Update; 2020 Feb; 26(2):141-160. PubMed ID: 32096862
[TBL] [Abstract][Full Text] [Related]
42. Frequency of discontinuation of contraceptive use: results from a French population-based cohort.
Moreau C; Bouyer J; Bajos N; Rodríguez G; Trussell J
Hum Reprod; 2009 Jun; 24(6):1387-92. PubMed ID: 19252195
[TBL] [Abstract][Full Text] [Related]
43. The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline.
Mavranezouli I;
Hum Reprod; 2008 Jun; 23(6):1338-45. PubMed ID: 18372257
[TBL] [Abstract][Full Text] [Related]
44. Differences in Contraceptive Discontinuation Among Black and White Women: Evidence from the Contraceptive CHOICE Project.
Allsworth JE; Secura GM; Ajibade OO; Peipert JF
J Womens Health (Larchmt); 2018 May; 27(5):599-606. PubMed ID: 29768114
[TBL] [Abstract][Full Text] [Related]
45. Attendance of an Initial Follow-up Visit after Long-Acting Reversible Contraception Insertion and Method Continuation Among Adolescents and Young Adults: A Retrospective Study.
Bryson AE; Cabral HJ; Coles MS
J Pediatr Adolesc Gynecol; 2021 Aug; 34(4):525-529. PubMed ID: 33486086
[TBL] [Abstract][Full Text] [Related]
46. Follow-Up Care and 6-Month Continuation Rates for Long-Acting Reversible Contraceptives in Adolescents and Young Adults: A Retrospective Chart Review.
Jones AE; Kaul S; Harding J; Weldon DLM; Akers AY
J Pediatr Adolesc Gynecol; 2020 Feb; 33(1):39-44. PubMed ID: 31513921
[TBL] [Abstract][Full Text] [Related]
47. Pooled incidence of continuation and pregnancy rates of four contraceptive methods in young women: a meta-analysis.
Farah D; Andrade TRM; Di Bella ZIKJ; Girão MJBC; Fonseca MCM
Eur J Contracept Reprod Health Care; 2022 Apr; 27(2):127-135. PubMed ID: 34431421
[TBL] [Abstract][Full Text] [Related]
48. Twenty-four-month continuation of reversible contraception.
O'Neil-Callahan M; Peipert JF; Zhao Q; Madden T; Secura G
Obstet Gynecol; 2013 Nov; 122(5):1083-1091. PubMed ID: 24104781
[TBL] [Abstract][Full Text] [Related]
49. Long-acting reversible contraception.
Peck SA
Nurs Womens Health; 2013 Oct; 17(5):431-5. PubMed ID: 24138662
[TBL] [Abstract][Full Text] [Related]
50. Young Age, Nulliparity, and Continuation of Long-Acting Reversible Contraceptive Methods.
Abraham M; Zhao Q; Peipert JF
Obstet Gynecol; 2015 Oct; 126(4):823-829. PubMed ID: 26348177
[TBL] [Abstract][Full Text] [Related]
51. Real-world cost-effectiveness of etonogestrel implants compared to long-term and short term reversible contraceptive methods in France.
Linet T; Lévy-Bachelot L; Farge G; Crespi S; Yang JZ; Robert J; Fabron C
Eur J Contracept Reprod Health Care; 2021 Aug; 26(4):303-311. PubMed ID: 33960248
[TBL] [Abstract][Full Text] [Related]
52. Study of long-acting reversible contraceptive use in a UK primary care database: validation of methodology.
Cea Soriano L; Wallander MA; Andersson SW; Requena G; García-Rodríguez LA
Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):22-8. PubMed ID: 24229345
[TBL] [Abstract][Full Text] [Related]
53. Comparison of contraceptive sales before and during the COVID-19 pandemic in Brazil.
Charles CM; Munezero A; Bahamondes LG; Pacagnella RC
Eur J Contracept Reprod Health Care; 2022 Apr; 27(2):115-120. PubMed ID: 35156489
[TBL] [Abstract][Full Text] [Related]
54. Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France.
Roland N; Drouin J; Desplas D; Duranteau L; Cuenot F; Dray-Spira R; Weill A; Zureik M
Contraception; 2022 Apr; 108():50-55. PubMed ID: 34971603
[TBL] [Abstract][Full Text] [Related]
55. Does Obesity Influence Body Mass Index Changes in Nulliparous Adolescent Users of Long-Acting Reversible Contraceptives?
Scott N; Silver EJ; Dodson NA; Coupey SM
J Pediatr Adolesc Gynecol; 2021 Dec; 34(6):815-820. PubMed ID: 34389461
[TBL] [Abstract][Full Text] [Related]
56. Postpartum contraception: initiation and effectiveness in a large universal healthcare system.
Brunson MR; Klein DA; Olsen CH; Weir LF; Roberts TA
Am J Obstet Gynecol; 2017 Jul; 217(1):55.e1-55.e9. PubMed ID: 28257962
[TBL] [Abstract][Full Text] [Related]
57. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
58. The continuation rates of long-acting reversible contraceptives in UK general practice using data from The Health Improvement Network.
Cea Soriano L; Wallander MA; Andersson S; Filonenko A; García Rodríguez LA
Pharmacoepidemiol Drug Saf; 2015 Jan; 24(1):52-8. PubMed ID: 25250863
[TBL] [Abstract][Full Text] [Related]
59. Contraceptive use in the Nordic countries.
Lindh I; Skjeldestad FE; Gemzell-Danielsson K; Heikinheimo O; Hognert H; Milsom I; Lidegaard Ø
Acta Obstet Gynecol Scand; 2017 Jan; 96(1):19-28. PubMed ID: 27861709
[TBL] [Abstract][Full Text] [Related]
60. Six-month and 1-year continuation rates following postpartum insertion of implants and intrauterine devices.
Woo I; Seifert S; Hendricks D; Jamshidi RM; Burke AE; Fox MC
Contraception; 2015 Dec; 92(6):532-5. PubMed ID: 26408376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
